MOR Stock Overview
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
MorphoSys AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €67.70 |
52 Week High | €68.00 |
52 Week Low | €14.52 |
Beta | 0.60 |
1 Month Change | 1.80% |
3 Month Change | 102.09% |
1 Year Change | 269.84% |
3 Year Change | -13.14% |
5 Year Change | -22.32% |
Change since IPO | 902.97% |
Recent News & Updates
Recent updates
MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up
Dec 25Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?
Aug 24Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?
May 16MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%
Apr 17MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be
Nov 26News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat
Mar 21MorphoSys AG (ETR:MOR) Analysts Just Slashed Next Year's Revenue Estimates By 10%
Jan 12Shareholder Returns
MOR | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.1% | -4.3% | -2.5% |
1Y | 269.8% | -19.4% | -0.4% |
Return vs Industry: MOR exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: MOR exceeded the German Market which returned -0.4% over the past year.
Price Volatility
MOR volatility | |
---|---|
MOR Average Weekly Movement | 12.3% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MOR's share price has been volatile over the past 3 months.
Volatility Over Time: MOR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 524 | Jean-Paul Kress | www.morphosys.com |
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
MorphoSys AG Fundamentals Summary
MOR fundamental statistics | |
---|---|
Market cap | €2.55b |
Earnings (TTM) | -€189.73m |
Revenue (TTM) | €238.28m |
10.7x
P/S Ratio-13.4x
P/E RatioIs MOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MOR income statement (TTM) | |
---|---|
Revenue | €238.28m |
Cost of Revenue | €58.35m |
Gross Profit | €179.92m |
Other Expenses | €369.66m |
Earnings | -€189.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
Earnings per share (EPS) | -5.04 |
Gross Margin | 75.51% |
Net Profit Margin | -79.63% |
Debt/Equity Ratio | 3,428.8% |
How did MOR perform over the long term?
See historical performance and comparison